Beovu FDA Approval History
Reviewed by J.Stewart BPharm. Last updated on Oct 9, 2019.
FDA Approved: Yes (First approved October 7, 2019)
Brand name: Beovu
Generic name: brolucizumab-dbll
Dosage form: Injection
Company: Novartis Pharmaceuticals Corporation
Treatment for: Macular Degeneration
Beovu (brolucizumab-dbll) is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).
- By inhibiting VEGF, Beovu works to suppress the growth of abnormal blood vessels under the macula and reduce the potential for vision loss caused by fluid leakage into the retina.
- Beovu is administered by intravitreal injection into the vitreous cavity of the eye every month for the first three doses, then every 8-12 weeks.
- Common side effects include: vision blurred, cataract, conjunctival hemorrhage, vitreous floaters, and eye pain.
Development Timeline for Beovu
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.